CD28-SuperMAB Uses, Dosage, Side Effects and more
CD28-SuperMAB is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).
| Attribute | Details |
|---|---|
| Trade Name | CD28-SuperMAB |
| Generic | Theralizumab |
| Theralizumab Other Names | CD28-SuperMAB, Theralizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
